Journal of Clinical Oncology
Articles in this Issue
Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.
759 Background: The 1L treatment landscape in la/mUC has evolved rapidly, encompassing platinum-based chemotherapy, immune checkpoint inhibitors (ICIs), a...
Plasma proteome-based integrative prognostic nomogram in metastatic castrate-resistant prostate cancer (mCRPC).
225 Background: Currently non-specific clinical factors including non-tumor biology proteins (Alkaline Phosphatase-ALK, LDH, albumin) are used for identif...
Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes.
593 Background: Immune checkpoint inhibitors (ICIs) are a mainstay of treatment for metastatic clear cell renal cell carcinoma (mccRCC). With a growing nu...
Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.
252 Background: Liquid biopsy assays in mCRPC are utilized for treatment eligibility of PARP inhibitors (HRR) and Pembrolizumab (MSI High). These ctDNA ta...
Unraveling the dietary impact: Associations between ultra-processed foods and prostate cancer in a two-decade study.
135 Background: Prostate cancer is a leading cause of cancer-related morbidity in men, and emerging research suggests that dietary patterns, particularly...
A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).
TPS898 Background: Zelenectide pevedotin (zele; BT8009) is a Bicycle Toxin Conjugate (BTC), comprising a highly selective bicyclic peptide targeting Necti...
Lewis Y antigen as a novel target for CAR (chimeric antigen receptor) T-cell therapy in patients with neuroendocrine prostate cancer.
217 Background: Neuroendocrine prostate cancers (NEPC) currently have no effective therapies. While CAR (Chimeric Antigen Receptor) T cell therapies targe...
Real-world community oncology-based treatment patterns for first line axitinib plus pembrolizumab in advanced renal cell carcinoma: Initial dosing, dose reductions and clinical outcomes.
487 Background: Axitinib (AXI) with pembrolizumab (PEM) is approved for first line (1L) treatment of advanced renal cell carcinoma (aRCC). This study prov...
A natural language processing algorithm to extract MRI and biopsy-related phenotypes for prostate cancer patients.
356 Background: Extraction of data from unstructured medical records is a powerful but challenging tool for deriving novel information to drive research,...
Evaluating the combined role of HHLA2 and PD-L1 as biomarkers in first-line nivolumab therapy in advanced clear cell renal cell carcinoma.
598 Background: PD-1 directed immune checkpoint inhibitors are effective in many tumor types, including kidney cancers. HHLA2 is a negative immune checkpo...
Survival disparities by race in advanced urothelial carcinoma (aUC): A real-world analysis.
668 Background: Retrospective population data suggest poorer survival for non-White aUC patients. However, data on survival disparities in the era of immu...
ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
808 Background: Erdafitinib (E) is an approved treatment in patients with mUCwith FGFR 3 GAs after progression on platinum-based chemotherapy (PBC). Enfor...
First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of <sup>64</sup> Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).
TPS605 Background: Carbonic Anhydrase (CA)IX is a type of carbonic anhydrase and is expected to be a useful target for detecting tumors with poor prognosi...
Immune profiling at the single-cell level to evaluate the immune microenvironment in bladder cancer: Insights from non-muscle invasive and muscle-invasive disease.
842 Background: Advanced Bladder Cancer (BC) presents significant challenges due to its high incidence and limited treatment options. Most patients initia...
Disease management costs and healthcare resource utilization by progression health state among patients with previously untreated locally advanced or metastatic urothelial cancer.
714 Background: Significant disease management cost (DMC) burden and healthcare resource utilization (HRU) have been reported for patients with advanced b...
Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma (RCC) patients: Results from 3-year follow-up of the phase 2 pilot study.
536 Background: Some patients with primary renal cell carcinoma (RCC) are not candidates for surgery or nephron-sparing interventions due to various facto...
Real-world comparison of cost and adherence between patients receiving low-dose versus standard-dose abiraterone acetate (AA) in a safety-net hospital.
54 Background: While the standard dose of AA (1,000 mg) is taken on an empty stomach, low-dose AA (250 mg with a low-fat meal) is also an option, with bot...
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
LBA141 Background: Approximately one-quarter of advanced prostate cancers have alterations in DNA damage response genes directly or indirectly involved wi...
Deciphering immune-genomic markers of hyperprogression in patients (Pts) with metastatic urothelial cancer (mUC) treated with immune checkpoint inhibitors (ICIs).
840 Background: ICIs offer modest response rates (~20%) in mUC and there remains a critical need for validated biomarkers to predict patient benefit. Hype...